Review




Structured Review

MultiTarget Pharmaceuticals stool dna test mt-sdna
Stool Dna Test Mt Sdna, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mt-sdna+test/stool+dna++mt+sdna++testing/pmc10185295-59-9-8
Average 90 stars, based on 1 article reviews
stool dna test mt-sdna - by Bioz Stars, 2026-11
90/100 stars

Images

Related Articles

other:

Article Title: Evaluation of a Tailored Patient Navigation Program for Improving Multitarget Stool DNA Test Adherence.
Article Snippet: BACKGROUND: Multitarget stool DNA (mt-sDNA) is an increasingly utilized noninvasive option for colorectal cancer screening; however, its impact is limited by imperfect test adherence.. Tailored patient navigation (TPN) improves adherence for other cancer screening tests, but its role in mt-sDNA is not known.. AIM: Determine whether TPN improves mt-sDNA completion and reduces sample could not be processed (SCNBP) result rates.

Article Title: Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer
Article Snippet: APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Article Title: Effects of Academic Detailing, Panel Management and Mailed Multi-Target Stool-DNA Testing on Colorectal Cancer Screening
Article Snippet: Colorectal cancer (CRC) has the third highest cancer incidence among both men and women in the United States with 80,690 new cases in men and 70,340 new cases in women based on 2022 estimates.1 Colorectal cancer is the third most common cause of cancer mortality for males (28,400 deaths) and females (24,180 deaths) in the US based on 2022 estimates.1 Screening for colorectal cancer is recommended for asymptomatic men and women ages 50–75 (ages 45–49 grade B recommendation) at average risk via the following: colonoscopy every 10year; flexible sigmoidoscopy every 10 years1 Fecal Immunochemical Test (FIT) every year; flexible sigmoidoscopy every 5 years; CT colonography every 5years; multitarget stool DNA test (sDNA-FIT) every 1–3years or highsensitivity guaiac fecal occult blood test (gFOBT) or Fecal ImmunochemicalTest (FIT) test annually.2 Despite multiple effective screening methods, CRC screening is often underutilized.

Article Title: Positive Predictive Value for Multitarget Stool DNA After Bariatric and Metabolic Surgery
Article Snippet: Multitarget stool DNA (mt-sDNA) is approved for CRC screening; however, performance in post-BMS patients is unknown.

Article Title: Stool-based testing for post-polypectomy colorectal cancer surveillance safely reduces colonoscopies: The MOCCAS study.
Article Snippet: Test characteristics of the mt-sDNA test in the post-polypectomy group at the thresholds used in the biennial and the triennial strategies that are at least equivalent to colonoscopy surveillance. a N = 2226 Colonoscopy Multitarget Stool DNA Test Score ≥ 270 (Biennial testing) Score ≥ 185 (Triennial testing) Cases Positive cases Sensitivity (95% CI) Positive cases Sensitivity (95% CI) Advanced neoplasia 322 146 45% (40-51%) 189 59% (53-64%) Colorectal cancer 7 6 86% (42-99%) 6 86% (42-99%) Advanced adenomas 222 90 41% (34-47%) 114 51% (45-58%) Advanced serrated polyps 93 50 54% (43-64%) 69 74% (63-82%) Non-advanced neoplasia 993 193 19% (17-22%) 301 30% (27-33%) Non-advanced adenomas 789 149 19% (16-22%) 225 29% (25-32%) Non-advanced serrated polyps 204 44 22% (16-28%) 76 37% (31-44%) Controls Negative controls Specificity (95% CI) Negative controls Specificity (95% CI) No colorectal neoplasia b 911 795 87% (85-89%) 722 79% (76-82%) No lesions 716 628 88% (85-90%) 577 81% (77-83%) a Annual testing with the mt-sDNA test was considered not relevant, due to the high costs of the test and was therefore not evaluated. b Colorectal neoplasia = colorectal cancer, advanced adenoma, advanced serrated polyp, non-advanced adenoma, and non-advanced serrated polyp.

Article Title: Stool-based testing for post-polypectomy colorectal cancer surveillance safely reduces colonoscopies: The MOCCAS study.
Article Snippet: Stool-based tests, like FIT or the FDA-approved 140 multitarget stool DNA (mt-sDNA) test9, could be possible alternatives for CRC surveillance.

Article Title: Characteristics of a cost-effective blood test for colorectal cancer screening
Article Snippet: Sensitivity to detect advanced adenomas spans the false-positive rate under the CMS coverage decision (10%), and the maximum sensitivity to advanced adenomas explored (50%) goes beyond the advanced adenoma sensitivity of any existing noninvasive test: sensitivity to advanced adenomas for mt-sDNA was 42% for the first-generation test , 43.4% for the next-generation mt-sDNA test , and 46% for a multitarget stool RNA test ( ).

Marker:

Article Title: Colorectal cancer screening: A review of current knowledge and progress in research
Article Snippet: .. Multitarget stool DNA (mts DNA): The mtsDNA test combines a FIT with assays for several molecular marker, namely mutant KRAS and β-actin, and also abnormally methylated regions of DNA from advanced adenomas or CRC associated with colorectal carcinogenesis, including methylated bone morphogenetic protein 3 (BMP3) and methylated N-Myc downstream-regulated gene 4 protein (NDRG4). ..

Mutagenesis:

Article Title: Colorectal cancer screening: A review of current knowledge and progress in research
Article Snippet: .. Multitarget stool DNA (mts DNA): The mtsDNA test combines a FIT with assays for several molecular marker, namely mutant KRAS and β-actin, and also abnormally methylated regions of DNA from advanced adenomas or CRC associated with colorectal carcinogenesis, including methylated bone morphogenetic protein 3 (BMP3) and methylated N-Myc downstream-regulated gene 4 protein (NDRG4). ..

Methylation:

Article Title: Colorectal cancer screening: A review of current knowledge and progress in research
Article Snippet: .. Multitarget stool DNA (mts DNA): The mtsDNA test combines a FIT with assays for several molecular marker, namely mutant KRAS and β-actin, and also abnormally methylated regions of DNA from advanced adenomas or CRC associated with colorectal carcinogenesis, including methylated bone morphogenetic protein 3 (BMP3) and methylated N-Myc downstream-regulated gene 4 protein (NDRG4). ..



Similar Products

90
Wolters Kluwer Health mt-sdna screening test
Mt Sdna Screening Test, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mt-sdna+test/mt+sdna+screening+test/pm40569294-115-19-2
Average 90 stars, based on 1 article reviews
mt-sdna screening test - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Exact Sciences Corporation multi-target stool dna (mt-sdna) test (marketed as cologuard)
Multi Target Stool Dna (Mt Sdna) Test (Marketed As Cologuard), supplied by Exact Sciences Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mt-sdna+test/multi+target+stool+dna+test+cologuard/pm39992481-15-13-27
Average 90 stars, based on 1 article reviews
multi-target stool dna (mt-sdna) test (marketed as cologuard) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Guardant Health triennial mt-sdna test
Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy
Triennial Mt Sdna Test, supplied by Guardant Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mt-sdna+test/triennial+mt+sdna+test/pmc11739995-70-12-21
Average 90 stars, based on 1 article reviews
triennial mt-sdna test - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MultiTarget Pharmaceuticals mt-sdna test
Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy
Mt Sdna Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mt-sdna+test/stool+dna++mt+sdna++testing/pmc11461157-58-51-59
Average 90 stars, based on 1 article reviews
mt-sdna test - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MultiTarget Pharmaceuticals stool dna (mt-sdna) test
Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy
Stool Dna (Mt Sdna) Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mt-sdna+test/stool+dna++mt+sdna++testing/pm39218164-91-9-8
Average 90 stars, based on 1 article reviews
stool dna (mt-sdna) test - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MultiTarget Pharmaceuticals next-generation mt-sdna test
<t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
Next Generation Mt Sdna Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mt-sdna+test/stool+dna++mt+sdna++testing/pmc11401593-148-55-13
Average 90 stars, based on 1 article reviews
next-generation mt-sdna test - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Exact Sciences Corporation mt-sdna tests
<t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
Mt Sdna Tests, supplied by Exact Sciences Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mt-sdna+test/mt+sdna+tests/pmc10964930-100-8-25
Average 90 stars, based on 1 article reviews
mt-sdna tests - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Exact Sciences Corporation multi-target stool dna (mt-sdna) screening test
<t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
Multi Target Stool Dna (Mt Sdna) Screening Test, supplied by Exact Sciences Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mt-sdna+test/multi+target+stool+dna+test+cologuard/pmc10666720-104-13-26
Average 90 stars, based on 1 article reviews
multi-target stool dna (mt-sdna) screening test - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy

Journal: JAMA Network Open

Article Title: Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics

doi: 10.1001/jamanetworkopen.2024.54938

Figure Lengend Snippet: Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy

Article Snippet: We simulated 4 screening strategies: no screening, annual FIT, biennial FIT, , triennial mt-sDNA test, and a triennial blood test (Shield; Guardant Health).

Techniques:

Projected CRC Outcomes for Screening Programs Based on a FIT, mt-sDNA Test, or a Blood-Based Test <xref ref-type= a " width="100%" height="100%">

Journal: JAMA Network Open

Article Title: Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics

doi: 10.1001/jamanetworkopen.2024.54938

Figure Lengend Snippet: Projected CRC Outcomes for Screening Programs Based on a FIT, mt-sDNA Test, or a Blood-Based Test a

Article Snippet: We simulated 4 screening strategies: no screening, annual FIT, biennial FIT, , triennial mt-sDNA test, and a triennial blood test (Shield; Guardant Health).

Techniques:

Projected Cost-Effectiveness Outcomes <xref ref-type= a " width="100%" height="100%">

Journal: JAMA Network Open

Article Title: Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics

doi: 10.1001/jamanetworkopen.2024.54938

Figure Lengend Snippet: Projected Cost-Effectiveness Outcomes a

Article Snippet: We simulated 4 screening strategies: no screening, annual FIT, biennial FIT, , triennial mt-sDNA test, and a triennial blood test (Shield; Guardant Health).

Techniques:

ROC curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation mt-sDNA tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Journal: Gastro Hep Advances

Article Title: Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer

doi: 10.1016/j.gastha.2024.05.002

Figure Lengend Snippet: ROC curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation mt-sDNA tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Article Snippet: APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Techniques:

Performance of the Next-Generation mt-sDNA Test Compared With Historical Performance of the  First-Generation mt-sDNA Test  in the DeeP-C Test Set

Journal: Gastro Hep Advances

Article Title: Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer

doi: 10.1016/j.gastha.2024.05.002

Figure Lengend Snippet: Performance of the Next-Generation mt-sDNA Test Compared With Historical Performance of the First-Generation mt-sDNA Test in the DeeP-C Test Set

Article Snippet: APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Techniques: